- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| ABVC BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| 14.08. | ABVC BIOPHARMA, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 27.06. | ABVC BIOPHARMA, INC. - S-8, Securities to be offered to employees in employee benefit plans | 15 | SEC Filings | ||
| 04.06. | ABVC BIOPHARMA, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.11.24 | ABVC BioPharma, Inc. Reports Q3 2024 Financial Results and Operational Milestones | 222 | GlobeNewswire (Europe) | ABVC BioPharma Achieved its First Operational Profit, with a 102% Improvement over the Third Quarter of Last Year.Incremental Payments Received based on Executed Global Licensing Agreements that could... ► Artikel lesen |
4 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NANOREPRO | 1,785 | +3,78 % | Original-Research: NanoRepro AG (von GBC AG): Kaufen | Original-Research: NanoRepro AG - von GBC AG
09.10.2025 / 12:00 CET/CEST
Veröffentlichung einer Research, übermittelt durch EQS News - ein Service der EQS Group.
Für den Inhalt der Mitteilung bzw.... ► Artikel lesen | |
| BIOXXMED | 0,120 | 0,00 % | PTA-News: bioXXmed AG: Einladung zur ordentlichen Hauptversammlung | DJ PTA-News: bioXXmed AG: Einladung zur ordentlichen Hauptversammlung
Unternehmensmitteilung für den Kapitalmarkt
bioXXmed AG: Einladung zur ordentlichen Hauptversammlung
Heidelberg... ► Artikel lesen | |
| SIRONA BIOCHEM | 0,037 | -100,00 % | Sirona Biochem Corp.: Sirona Biochem Update to Shareholders on Financial Status and Operations | VANCOUVER, British Columbia, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) ("Sirona") wishes to provide shareholders with a critical update on the company's financial... ► Artikel lesen | |
| REDHILL BIOPHARMA | 1,570 | 0,00 % | RedHill Biopharma Receives Nasdaq Staff Determination Notification | On October 16, 2025, the Company received a Staff Determination notification from The Nasdaq Stock Market LLC regarding continued non-compliance with the minimum... ► Artikel lesen | |
| CELLECTIS | 3,285 | +4,29 % | Cellectis Reports Second Quarter 2025 Financial Results & Business Updates | Cellectis to host an Investor R&D Day in New York City on October 16, 2025: Phase 1 dataset and late-stage development strategy for lasme-cel (UCART22) in r/r B-ALL to be presented End-of-Phase 1... ► Artikel lesen | |
| ALTERITY THERAPEUTICS | 0,005 | 0,00 % | ALTERITY THERAPEUTICS LTD - 6-K, Report of foreign issuer | ||
| BIORA THERAPEUTICS | 0,001 | -100,00 % | NSE - BIORA THERAPEUTICS, INC. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | ||
| SERES THERAPEUTICS | 15,500 | +5,59 % | Seres Therapeutics, Inc.: Seres Therapeutics Announces Further Constructive Feedback from FDA on SER-155 Phase 2 Study Protocol and Implements Cost Reduction Actions to Extend Cash Runway | Following recent constructive FDA feedback, Seres anticipates finalizing SER-155 Phase 2 study protocol for the prevention of bloodstream infections in adults undergoing allogeneic hematopoietic stem... ► Artikel lesen | |
| WINDTREE THERAPEUTICS | 0,108 | -1,82 % | WINDTREE THERAPEUTICS INC /DE/ - S-1, General form for registration of securities | ||
| ALTAMIRA THERAPEUTICS | 0,300 | 0,00 % | Altamira Therapeutics Provides Business Update and First Half 2025 Financial Results | Company to host webcast today at 8.00 a.m. ETGrowing portfolio of RNA delivery clients and programsAdvancing plans for partial spin-off of RNA delivery activitiesContinued adjustment of cost structure... ► Artikel lesen | |
| MONOPAR THERAPEUTICS | 70,00 | +0,72 % | Monopar Therapeutics Inc.: Monopar Therapeutics Reports Second Quarter 2025 Financial Results and Recent Developments | WILMETTE, Ill., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. ("Monopar" or the "Company") (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative... ► Artikel lesen | |
| CLEARMIND MEDICINE | 0,886 | +2,61 % | Clearmind Medicine Inc.: Clearmind Medicine Appoints Mary-Elizabeth Gifford as Chief of Global Impact to Advance US Partnerships and Governmental Engagement | Vancouver, Canada, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on discovery and development... ► Artikel lesen | |
| SCISPARC | 3,810 | 0,00 % | SciSparc Ltd: SciSparc Announces Closing of the Acquisition of a Publicly Traded Company on the TSXV to which it transferred its Advanced Clinical Stage Pharmaceutical Portfolio | TEL AVIV, Israel, Oct. 24, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies... ► Artikel lesen | |
| ADITXT | 0,192 | 0,00 % | Evofem Biosciences, Inc.: Evofem Anticipates Approval of Merger with Aditxt at Upcoming Stockholder Meeting | -- Special Meeting to be held on September 26, 2025 --
SAN DIEGO, Sept. 9, 2025 /PRNewswire/ -- In an update to stockholders today, Evofem Biosciences, Inc.... ► Artikel lesen | |
| ENSYSCE BIOSCIENCES | 2,130 | 0,00 % | Ensysce Biosciences Releases Symposium Highlights from PAINWeek 2025 | ~ Pain Management, RE-Invented: Ushering in a New Era for Analgesia ~ SAN DIEGO, CA / ACCESS Newswire / October 10, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage... ► Artikel lesen |
Das Unternehmen ABVC BIOPHARMA INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 2,870 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ABVC BIOPHARMA INC finden Sie auf Wallstreet Online.